Amphastar P (AMPH) - Total Assets
Based on the latest financial reports, Amphastar P (AMPH) holds total assets worth $1.65 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Amphastar P service its debt to assess how comfortably operating cash covers total debt obligations.
Amphastar P - Total Assets Trend (2012–2025)
This chart illustrates how Amphastar P's total assets have evolved over time, based on quarterly financial data. See AMPH total equity for net asset value and shareholders' equity analysis.
Amphastar P - Asset Composition Analysis
Current Asset Composition (December 2025)
Amphastar P's total assets of $1.65 Billion consist of 39.0% current assets and 61.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.4% |
| Accounts Receivable | $143.56 Million | 8.8% |
| Inventory | $176.89 Million | 10.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $562.56 Million | 34.5% |
| Goodwill | $3.40 Million | 0.2% |
Asset Composition Trend (2012–2025)
This chart illustrates how Amphastar P's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Amphastar P.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amphastar P's current assets represent 39.0% of total assets in 2025, a decrease from 52.2% in 2012.
- Cash Position: Cash and equivalents constituted 10.4% of total assets in 2025, down from 15.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 13.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 34.5% of total assets.
Amphastar P Competitors by Total Assets
Key competitors of Amphastar P based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Amphastar P - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.85 | 2.95 | 2.50 |
| Quick Ratio | 2.82 | 2.02 | 1.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $469.20 Million | $388.91 Million | $186.42 Million |
Amphastar P - Advanced Valuation Insights
This section examines the relationship between Amphastar P's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | 3.3% |
| Total Assets | $1.63 Billion |
| Market Capitalization | $854.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Amphastar P's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Amphastar P's assets grew by 3.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Amphastar P (2012–2025)
The table below shows the annual total assets of Amphastar P from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.63 Billion | +3.29% |
| 2024-12-31 | $1.58 Billion | +4.27% |
| 2023-12-31 | $1.51 Billion | +103.90% |
| 2022-12-31 | $741.99 Million | +10.49% |
| 2021-12-31 | $671.53 Million | +6.38% |
| 2020-12-31 | $631.24 Million | +7.54% |
| 2019-12-31 | $586.97 Million | +14.29% |
| 2018-12-31 | $513.56 Million | +12.95% |
| 2017-12-31 | $454.67 Million | +6.30% |
| 2016-12-31 | $427.74 Million | +9.64% |
| 2015-12-31 | $390.14 Million | +0.20% |
| 2014-12-31 | $389.37 Million | +14.94% |
| 2013-12-31 | $338.75 Million | +6.70% |
| 2012-12-31 | $317.48 Million | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more